Erufosine

Overview

Erufosine is an inhibitor of PI3K/Akt and Ras/Raf/MAPK signaling pathways. Erufosine inhibits the activity of breast cancer cell lines MCF-7 and MDA-MB 231 ( IC 50 : 40.95/40.8 μM). Erufosine reduces the phosphorylation of PI3K (p85), Akt (PKB), and cRaf. Erufosine can be used in the study of breast cancer and myeloid leukemia.

Application

Products | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Ras | Products > Signaling Pathways > Raf | Products > Signaling Pathways > p38 MAPK

Product Information

• Catalog No.: HY-171777
• CAS No.: 202867-33-2
• Molecular Formula: C28H58NO4P
• Molecular Weight: 503.74
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source